Plasma tau and p-tau changes across groups in Tau SILK discovery cohort. (A) Measures of p-tau-217/T217 ratios in plasma and CSF are highly correlated in both entire cohort and CSF p-tau-217 positive subgroup. Spearman correlations and associated P value are shown. (B–E) Separation between amyloid-negative and -positive groups are calculated using AUROC. (B and C) Consistent with CSF measurement, plasma p-tau-217/T217 ratio and p-tau-217 level distinguish amyloid-negative from amyloid-positive groups regardless of the cognitive status. Amyloid-negative groups with high CSF p-tau-217 were also separated from other amyloid-negative groups. (D) Plasma tau level is not a biomarker for amyloid status and AD dementia. (E and F) Plasma p-tau-181/T181 ratio and p-tau-181 level increase in amyloid-positive groups. YNC, young normal controls; AMC, aged-matched controls.
Figure 2.

Plasma tau and p-tau changes across groups in Tau SILK discovery cohort. (A) Measures of p-tau-217/T217 ratios in plasma and CSF are highly correlated in both entire cohort and CSF p-tau-217 positive subgroup. Spearman correlations and associated P value are shown. (B–E) Separation between amyloid-negative and -positive groups are calculated using AUROC. (B and C) Consistent with CSF measurement, plasma p-tau-217/T217 ratio and p-tau-217 level distinguish amyloid-negative from amyloid-positive groups regardless of the cognitive status. Amyloid-negative groups with high CSF p-tau-217 were also separated from other amyloid-negative groups. (D) Plasma tau level is not a biomarker for amyloid status and AD dementia. (E and F) Plasma p-tau-181/T181 ratio and p-tau-181 level increase in amyloid-positive groups. YNC, young normal controls; AMC, aged-matched controls.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal